← Leaderboards
John Eisenhardt Bergmann
Omeros Corporation
$476,876
Attributed
$476,876
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $239.4K · FY2009–10$250K$187.5K$125K$62.5K$0
'09
'10
Funding mix
By agency
NIH$476,876 · 1
By mechanism
R43$476,876 · 1
Top collaborators
No co-investigators on record.
Most similar at Omeros Corporation
Same institution · by research overlap
- Pat W Gray$697,020
- Thomas Anton Dudler$1,052,057
- Neil Cutshall$1,041,859
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectAgonistAreaBaseBinding (Molecular Function)BiologicalBrainCell LineCell MembraneCellsCell SurfaceCell Surface ProteinsCentral Nervous System AgentsClinical PharmacologyClone CellsCoupledCyclic AmpDatabasesDoseDrug Delivery SystemsDrug DiscoveryDrug IndustryDrug Resistance2-Cyclopentyl-5-(5-Isoquinolylsulfonyl)-6-Nitro-1h-Benzo(D)Imidazole